
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

39251678
72020
10.1038/s41598-024-72020-y
Article
New insights into the mechanisms of the extracellular matrix and its therapeutic potential in anaplastic thyroid carcinoma
Xia Jinkun jinkunxia@foxmail.com

1
Shi Yuyu 2
Chen Xinxu 3
1 https://ror.org/046q1bp69 grid.459540.9 0000 0004 1791 4503 Department of Vascular and Thyroid Surgery, Guizhou Provincial People’s Hospital, Guiyang, 550002 Guizhou China
2 https://ror.org/02kstas42 grid.452244.1 The Second Affiliated Hospital of Guizhou Medical University, Kaili, 550003 Guizhou China
3 https://ror.org/054767b18 grid.508270.8 Emergency Department, Fenggang County People’s Hospital, Fenggang, 564299 Guizhou China
9 9 2024
9 9 2024
2024
14 2097717 1 2024
3 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Anaplastic thyroid carcinoma (ATC) is the most aggressive thyroid cancer, and it has a poor prognosis and high probability of metastatic recurrence. The long-term survival of cancer cells depends on their ability to settle in a favorable environment. Cancer cells interact with other cells in the tumor microenvironment to shape the “soil” and make it suitable for cell growth by forming an extremely complex tumor ecosystem. The extracellular matrix (ECM) is an essential component of the tumor ecosystem, and its biological and mechanical changes strongly affect tumor invasion, metastasis, immune escape and drug resistance. Compared to normal tissues, biological processes, such as collagen synthesis and ECM signaling, are significantly activated in ATC tissues. However, how ATC triggers changes in the properties of the ECM and its interaction with the ECM remain poorly characterized. Therefore, an in-depth study of the regulatory mechanism of the abnormal activation of ECM signaling in ATC is highly important for achieving the therapeutic goal of exerting antitumor effects by destroying the “soil” in which cancer cells depend for survival. In this research, we revealed the aberrant activation state of ECM signaling in ATC progression and attempted to uncover the potential mechanism of action of ECM components in ATC, with the aim of providing new drug targets for ATC therapy.

Keywords

Anaplastic thyroid carcinoma
Extracellular matrix
Tumor microenvironment
Cancer-associated fibroblasts
Cancer therapy
Subject terms

Cancer
Immunology
the Guizhou Provincial People’s Hospital Talent Fund2023-41 Xia Jinkun issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Thyroid carcinoma is one of the most common malignant endocrine cancers, and its incidence is increasing annually1. Anaplastic thyroid carcinoma (ATC) is an extremely malignant subtype of thyroid cancer that accounts for approximately 2% of cases, with a median survival of only 3–7 months2. Conventional therapies have limited efficacy in patients with ATC, and ATC patients often have a poor prognosis due to tumor expansion and distant metastasis3. Most ATC patients are diagnosed with advanced-stage cancer and miss the opportunity for surgical treatment, and there are currently no efficacious treatments that increase the overall survival of ATC patients4,5. Therefore, it is necessary to understand the cellular mechanisms of ATC to develop effective therapeutic targets and improve the survival rate of patients with this malignancy.

The tumor microenvironment (TME) refers to the internal environment in which tumor cells arise and live, and it is a complex integrated system that contains cellular components, such as cancer cells, fibroblasts and inflammatory/immune cells, and non-cellular components, such as the extracellular matrix (ECM) and cytokines6. A growing body of evidence suggests that the TME is not a ‘silent bystander’ but rather an ‘active promoter of oncogenesis’ in the process of cancer development7. Hypoxia, chronic inflammation and immunosuppression are prominent features of the TME, and these components form a highly complicated molecular network that makes the microenvironment a “blind zone” for the body’s anti-tumor immune response and immune intervention8. Recent immunotherapies, including immune checkpoint inhibitors, adoptive cellular immunotherapy, and cancer vaccines, restore and strengthen the ability of immune components in the TME to recognize and kill cancer cells, and these agents have shown superior therapeutic effects in the specific clearing of tumors compared to conventional therapies9. For patients with ATC, targeted blockade of programmed death-1/programmed death ligand-1 at immune checkpoints or the combination of molecularly targeted inhibitors and immunotherapy have shown promising therapeutic outcomes10. However, the high heterogeneity of individual tumors and the frequent occurrence of immune resistance limit the benefits of immunotherapy, and some patients do not benefit from it11. Understanding the mechanisms of immune regulation in the ATC microenvironment deepens our understanding of tumor cell behavior and aids in the development of new drugs to improve the antitumor efficacy of immunotherapy.

The ECM is a non-cellular component that provides biochemical components and fundamental structural support to tumor cells in the TME12. The main components of the ECM include collagen (approximately 90% of the ECM), fibronectin, elastin, laminin, hyaluronic acid, chondroitin sulfate, keratan sulfate, and heparan sulfate, and their quantity and cross-linking status are the main determinants of tissue stiffness13. The ECM is used as an intercellular filler, and it is an active substance and source of signaling molecules for intercellular communication, cell proliferation, and adhesion14. Active interactions between cancer cells and the TME often result in stiffening of the ECM, which leads to aberrant mechanotransduction and further malignant transformation during cancer progression15. The clinical application of ibrutinib, which is a small molecule compound that inhibits integrin (ECM receptor) signaling, for the treatment of lymphoid leukemias and lymphomas has demonstrated the feasibility of targeting aberrantly activated ECM in oncotherapy16. Notably, some studies have revealed the critical role of ECM remodeling in ATC cell metastasis17. Therefore, a comprehensive understanding of ECM derangement in the TME may help identify promising targets for ATC therapy.

In this study, we emphasize the significant role of ECM in ATC progression and its potential therapeutic targets for antitumor by summarizing the following knowledge: (1) the activation status of the ECM in ATC; (2) the potential function of the main components of the ECM in ATC; (3) the potential impact of the interaction between cancer cells and the ECM in the TME on ATC progression; and (4) potential therapeutic strategies targeting aberrant ECM signaling for ATC treatment.

Materials and methods

ATC data of public databases

The transcription data (GSE29265, GSE33630, GSE53072, and GSE65144) were downloaded from the Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/).

Gene ontology (GO) and kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analyses

Differentially expressed genes (DEGs) among the normal and ATC groups were displayed in the form of volcano plots by the “gplot” R package from Assistant for Clinical Bioinformatics (https://www.aclbi.com/static/index.html#/) platform. |Fold Change|> 2 and adjusted p < 0.05 were set as the statistical threshold value for differentially expressed genes. GO and KEGG pathway analyses were performed by the Assistant for Clinical Bioinformatics platform using ClusterProfiler package in R software, based on relevant cancer data in GEO database (GSE29265, GSE33630, GSE53072, and GSE65144). In the enrichment result, p less than 0.05 is considered to be a meaningful pathway.

Results

ECM signaling is significantly activated in ATC tissues

The GEO is a shared repository for high-throughput microarray and next-generation sequence functional genomic datasets. To determine the status of activated ECM signaling in ATC, we downloaded and extracted transcriptome data and corresponding clinical information from the GSE29265, GSE33630, GSE53072, and GSE65144 datasets. Differentially expressed genes (DEGs) between ATC and normal tissue were identified, and enrichment analysis was performed as described previously18. Notably, the downregulated DEGs in the four GEO datasets were closely related to extracellular structure organization and extracellular matrix organization (Figs. 1, 2, 3, 4), which suggested that ECM signaling played a crucial role in ATC progression. The most significantly enriched terms for GSE29265 were organelle fission, nuclear division, mitotic nuclear division, extracellular structure organization, extracellular matrix organization, and chromosome segregation, as shown in Fig. 1. Similarly, the most significantly enriched terms for GSE33630 were extracellular structure organization, extracellular matrix organization, and cytokine–cytokine receptor interaction; the most significantly enriched terms for GSE53072 were Herpes simplex virus 1 infection, cytokine–cytokine receptor interaction, extracellular structure organization, and extracellular matrix organization; the most significantly enriched terms for GSE65144 were Herpes simplex virus 1 infection, cytokine–cytokine receptor interaction, extracellular structure organization, and extracellular matrix organization, and neutrophil degranulation, neutrophil activation involved in immune response, as shown in Figs. 2, 3 and 4, respectively. A distinguishing feature of ATC is its ability to easily shape the tumor stromal microenvironment. We listed several genes that exhibit aberrant expression in ATC tissues and are involved in modifying the ATC immune microenvironment in Table 1. Because of the important regulatory role of the ECM in the malignant phenotype of ATC, there is an urgent need to elucidate the mechanism of ECM remodeling in ATC.Fig. 1 Differentially expressed genes and enrichment analysis between ATC and normal tissues based on the GSE29265 dataset. A-B Volcano map (A) and heatmap (B) of differentially expressed genes was constructed on normal and ATC group. (C) The most significantly enriched terms for GSE29265 were organelle fission, nuclear division, mitotic nuclear division, extracellular structure organization, extracellular matrix organization, and chromosome segregation.

Fig. 2 Differentially expressed genes and enrichment analysis between ATC and normal tissues based on the GSE33630 dataset. A-B: Volcano map (A) and heatmap (B) of differentially expressed genes was constructed on normal and ATC group. (C) The most significantly enriched terms for GSE33630 were extracellular structure organization, extracellular matrix organization, and cytokine–cytokine receptor interaction.

Fig. 3 Differentially expressed genes and enrichment analysis between ATC and normal tissues based on the GSE53072 dataset. A-B: Volcano map (A) and heatmap (B) of differentially expressed genes was constructed on normal and ATC group. (C) The most significantly enriched terms for GSE53072 were Herpes simplex virus 1 infection, cytokine–cytokine receptor interaction, extracellular structure organization, and extracellular matrix organization.

Fig. 4 Differentially expressed genes and enrichment analysis between ATC and normal tissues based on the GSE65144 dataset. A-B: Volcano map (A) and heatmap (B) of differentially expressed genes was constructed on normal and ATC group. (C) The most significantly enriched terms for GSE65144 were Herpes simplex virus 1 infection, cytokine–cytokine receptor interaction, extracellular structure organization, and extracellular matrix organization, and neutrophil degranulation, neutrophil activation involved in immune response.

Table 1 Aberrant genes in ATC immune microenvironment.

Gene name	Differential expression in ATC	Biological processes/cellular functions	References	
METTL3	↓	increased the abundance of the immunosuppressive Tregs and terminally exhausted T cells	19	
SIGLEC15	↑	interacted with T cells by immunosuppressive signals such as CXCL12-CXCR4	20	
CD1d	↑	a receptor for NKT cells	21	
PPARGC1A	↑	inhibited immune cell infiltrations	22	
TLR4	↑	shaped the immunosuppressive microenvironment	23,24	

The function of the main components of the ECM in TME

Cancer cells remodel the ECM by interacting with stromal cells to promote covalent intermolecular cross-linking and the massive deposition of supramolecular aggregates, such as fibrillar collagens, and this ECM remodeling promotes tumor progression and influences cancer cell invasion25. Most proteins in the ECM are categorized into two groups, fibrous proteins (including collagen, fibronectin, elastin, and laminin) and glycosaminoglycan proteins (consisting of hyaluronic acid, chondroitin sulfate, keratan sulfate, and heparan sulfate)26.

Collagen

Fibroblasts primarily produce collagen, which is located in bones, tendons and skin27. Collagen accumulate in and around tumors during tumorigenesis progression and contribute to the promotion of tumor cell growth, metastasis, and drug resistance28,29. Notably, whether collagen deposition is a promoter or inhibitor in ATC progression remains controversial. Some collagens restrain cancer progression via multiple mechanisms, including inhibition of tumor proliferation by promoting cancer cells to enter and remain in a dormant state. Cancer cells in collagen-deficient tumors produce increased levels of chemokines to attract myeloid-derived suppressor cells (MDSCs), which induce an immunosuppressive microenvironment to limit the effectiveness of immunotherapy30,31. As a major component of the ECM, the quantity and post-translational modifications of collagen often change dramatically during cancer progression, which enable the construction of a complex collagenous mesh that has a fundamental impact on the behavior of cancer cells and other cells in the TME32,33. Collagen degradation is primarily governed by matrix metalloproteinases (MMPs). MMP-1, MMP-8, MMP-13, and MMP-14 cleave fibril-forming collagens I, II, and III, and MMP-2 and MMP-9 cleave denatured collagens and collagen IV34. Several collagen subtypes and MMPs are strongly associated with the development and progression of thyroid cancer, which suggests that remodeling of the ECM is a key feature of the TME that promotes the malignant processes of thyroid cancer and collagen subtypes and MMPs are candidate therapeutic targets and biomarkers for advanced stages of this malignancy35–37.

A recent single-cell transcriptomics study revealed that excessive activation of collagen and collagen-interacting receptors were critical processes in the malignant transformation of ATC38. Current studies elucidated the role of collagen in the ATC process from two main perspectives. One perspective is collagen synthesis and degradation. Many genes involved in collagen degradation affect the progression of ATC by altering collagen deposition39,40. The second perspective is the activation of cancer-associated fibroblasts (CAFs). Knockdown of CREB3L1 remodeled the tumor stromal microenvironment, and the presence of CAFs inhibited the growth of ATC spheroids and the metastasis of ATC cells41. Collagen is also produced from a subset of tumor cells42. We hypothesized that the state of collagen in ATC was a dynamic process, with alterations in components and content as cancer cells proliferate, expand and migrate. However, TAM-modified collagen also triggers signals that affect the interaction between cancer cells and surrounding mesenchymal cells or immune cells. There is also a great deal of variation in the collagen that borders or encapsulates the interior and exterior of the tumor tissue. The dynamic changes and differences in collagen, and the different sources of production, obscure its role in cancer progression. Therefore, constructing an intelligent model to reveal the progression status of ATC based on dynamic changes in collagen may be an effective approach.

Other components of the ECM

The content of fibronectin in the ECM is low. However, its role in tumor transformation should not be ignored, primarily because fibronectin connects various structural proteins to form an integrated matrix. Fibronectin also recognizes and binds integrins on the cell membrane and induces integrin attachment, which profoundly impacts intracellular signaling. Fibronectin binds directly to growth factors, such as insulin-like growth factor (IGF), fibroblast growth factor (FGF), transforming growth factor-β (TGF-β), hepatocyte growth factor (HGF), and platelet-derived growth factor (PDGF)43–46. Elastin is the main component of elastic fibers that maintains the toughness and strength of tissues by resisting tissue deformation or rupture together with collagen47,48. Laminin and collagen form the components of the basement membrane, which is involved in the process of vascular maturation49,50. Hyaluronic acid (HA) is a high molecular weight glycosaminoglycan that mechanically increases the elastic viscosity of the ECM51. HA also acts as a sieve to impede and immobilize large molecular particles that may be recognized by many types of cells during cell movement, invasion, proliferation and inflammation52,53. Despite the current lack of evidence confirming the role of these components of the ECM in the ATC process, their roles cannot be ignored. A recent study revealed that thyroid cancer cells cultured in different dimensional states differed significantly in hypoxia, ECM, cytoskeleton, thyroid-specific proteins, and thyroid transcription factors54. Three-dimensional spheroids from patients with thyroid cancer showed a decrease in the expression of thyroid differentiation markers54. Based on the essential role of ECM components in maintaining the spherical morphology of cancer cells, we hypothesized that these components played a crucial role in the malignant progression of ATC.

Fibroblasts

Fibroblasts directly produce structural macromolecules, such as collagen, fibronectin, and laminin, and secrete many enzymes involved in the modification and degradation of these structural macromolecules, such as lysyl hydroxylases and MMPs, to play a central role in the formation and renewal of the ECM55,56. Fibroblasts are highly flexible cells that convert signals from multiple sources, including TGF-β, tumor necrosis factor-alpha (TNF-α) and interleukin (IL)-1, repeated mechanical stretching, and repeated mild heat shocks, into alterations in ECM components57,58. Cancer-associated fibroblasts (CAFs), which originate primarily from mesenchymal cells and resident fibroblasts, are among the most important cell components in the TME of most solid tumors and are activated and reprogrammed in response to paracrine factors and cytokines produced and released by tumor cells59. Many studies suggest that fibroblast-mediated collagen remodeling within the TME facilitates the progression of thyroid cancers, and increased expression of CAFs is a risk factor for worse thyroid cancer clinicopathological features60–62. CAFs and senescent thyroid cancer cells co-occur in various histotypes of BRAF-driven thyroid tumors and localize at the tumor invasive front, which suggests that crosstalk between CAFs and thyroid cancer cells plays an essential role in the invasive process of thyroid tumors63. There is some evidence that the inhibition of the CAF-like properties of ATC cells via the blockade of ECM signaling, which remodels the tumor stromal microenvironment and drives malignancy in ATCs, may be a novel strategy for suppression of the malignant transformation of ATCs41. Fibroblasts are one of the major cell types in the TME, and targeting fibroblasts to block cell‒cell communication in ATC cells is an immunotherapeutic opportunity64.

Interaction of the ECM with TME components

Most cancers exhibit greater matrix stiffness (depending on the ECM components and proportions) than their corresponding normal tissues. Therefore, ECM stiffness is a unique feature and promising therapeutic target65,66. However, we hypothesize that the interaction of the ECM with cancer cells, stromal cells, and immune cells in the complex molecular regulatory network of the TME is the key to unraveling the malignant process of ATC. Chemokine-chemokine receptor interactions, such as the TGF-β/Smad2/3 and CXCL12/CXCR4 signaling pathways, are the most significant drivers of the transformation of normal fibroblasts to CAFs and macrophages to the M2 type of macrophages, which further facilitate ECM deposition and cancer malignancy67. This interaction also directly or indirectly affects ECM stiffness. Overall, the production of ECM components and enzymes is further accelerated when tumor cells receive external signals from growth factors. In contrast, some enzymes that catalyze ECM degradation are inhibited in the TME67. Notably, the upregulation of MMP activity in a stiffened TME also increases vascular proliferation, invasion, and neovascular branching68. The ECM acts as a reservoir for growth factors, and ECM degradation contributes to the release of growth factors and cytokines that facilitate cancer progression. However, the motility of cancer cells is activated when the local matrix is degraded, which further confirms the complexity and dynamics of the ECM regulatory network.

The ECM in the TME promotes the proliferation, migration and vascularization of cancer cells and the transformation of tumor cells to cancer stem cells (CSCs). Cancer cells hijack surrounding stromal cells, immune cells, inflammatory cells, and the ECM is a vehicle for inducing cancer cell expansion. The specific pathways and mechanisms involved have been detailed previously67. The ECM acts as a physical barrier and compresses micro blood vessels or causes them to leak, which partially reduces the efficacy of chemotherapies and immune therapies66,69. The negative effect of the ECM on the infiltration of tumor-killing immune cells in the TME is also well understood. The tumor-killing immune cells are more inclined to migrate during the ECM-rich encapsulation of tumors. ECM-rich tumors create a hypoxic environment that allows enhanced glycolytic metabolism and acidification, which further induces an immunosuppressive microenvironment70. ECM proteins also directly enhance the activity of Tregs to induce cancer cells to express more PD-L1, or drive M2 polarization, which inhibits CD8+ T-cell-mediated anti-tumor immune responses71,72. Altogether, these results suggest that the cross-talk between the ECM and microenvironmental cells largely controls cancer progression. Therefore, we hypothesize that aberrantly activated ECM signaling appears to be critical for the rapid expansion of ATC cells.

Receptors for the ECM in TME

Receptor proteins are important factors for ECM communication with the surrounding environment73. Many ECM-associated receptor proteins, including integrin, discoidin domain receptors (DDRs), CD44, and receptor for hyaluronan-mediated motility (RHAMM), are highly upregulated in many solid tumors and correlate with malignancy and poor prognosis74,75. Notably, inhibitors or antibodies against these receptors have been widely used in preclinical and clinical studies76. Cancer cells respond to their surroundings by sensing ECM-mediated mechanical stress or molecular stimuli via unidirectional (receptors sense ECM stiffness then transmit this signal to cells) or bidirectional (cells sense signals received by receptors and transmit signals through receptors) signaling driven by receptor proteins77. Notably, these receptors have a distinct division of labor, and different subtypes receive the corresponding ECM signals. For example, DDR1 binds to collagen types I and IV, and DDR2 interacts with collagen types I, II, and X. HA is the major ligand for membrane-bound RHAMM67. The binding of lymphocytes to fibronectin is also facilitated by CD44, which is critical for lymphocyte infiltration into the TME78,79. A preclinical trial demonstrated that recombinant fibronectin CH296 stimulated T cells to achieve robust tumor suppression in patients with advanced cancer80, which suggesting that blockade of ECM-cancer cell crosstalk is a potential anti-cancer strategy. This meticulous cross-linking constitutes a complex network of ECM-cancer cell interactions. We hypothesize that cancer cells hijack the ECM in the TME to sense changes in their surroundings and use it as a territory to send aggressive signals to surrounding or distant cells or organs. Cancer cells wrap surrounding normal cells via the ECM to form a tumor environment and construct an immunosuppressive microenvironment that is conducive to cancer cell expansion. We hypothesize that the rapid expansion of ATC is closely related to the dysregulation of ECM receptor signaling.

Matrix components as potential therapeutic targets for ATC

Drugs that inhibit collagen synthesis (halofuginone, Fresolimumab) or induce collagen degradation (collagenases) have been investigated extensively in animal and preclinical studies81,82. Mechanistically, these drugs weaken the stiffness of the ECM and contribute to more efficient drug delivery to solid tumors83–85. Several strategies aimed at modulating the number or activity of MMPs or approaches that indirectly increase the synthesis of collagenases also contribute to cancer therapy86. A number of drugs that use ECM components as therapeutic targets (e.g., 4-methylumbelliferone, which was designed to facilitate greater penetration of anticancer drugs into the interior of solid tumors) or that use ECM components as targets for precise drug delivery (BC-1, L19) also offer new opportunities for solid tumor therapy67. However, these methods have some drawbacks. The degradation of collagen releases many growth factors, and whether this release exacerbates the inflammatory response of tumors is not known, Whether ECM degradation contributes to cancer cell invasion must be further investigated. We postulated that the inhibition of collagen cross-linking is a novel strategy for inhibiting the progression of ATC. Lysyl oxidase (LOX, an ECM-remodeling enzyme) catalyzes collagen cross-linking and is frequently upregulated in thyroid cancer87. Several clinical trials confirmed the use of an anti-LOXL2 monoclonal antibody (simtuzumab) with no clinically significant effect in patients with pulmonary or hepatic fibrosis88,89. However, this unexpected negative result may be related to an ineffective antibody, and other members of the LOX family may be more appealing candidates for cancer treatment.

Significant breakthroughs in the past decade have been made in controlling cancer progression via targeted cell–ECM interactions. Collagen, proteoglycans, and glycoproteins also form ECM in the bone marrow and lymph nodes. However, unlike solid tumors, leukemia (so-called “liquid carcinoma”) cells form only temporary connections to the ECM in structured niches within the bone marrow and lymphoid organs90. Ibrutinib (an inhibitor of bruton tyrosine kinase) controls integrin α4β1-mediated adhesion to fibronectin, VCAM-1, and chemotaxis signals mediated by CXCL12-, CXCL13-, and CCL19-induced signaling, and it has been approved for patients with chronic lymphocytic leukemia (CLL)91. The RHAMM-HA interaction facilitates cell motility, but the RHAMM-R3 peptide vaccine triggered anti-cancer immune responses in CLL patients92,93. These results reveal that targeting cell-ECM interactions is a highly viable approach against malignant tumors, including ATCs.

Conclusion

ATC is a rare subtype of thyroid carcinoma and is extremely aggressive. Treating ATC in the traditional manner of treating differentiated thyroid tumors is ineffective in most cases, and due to the highly aggressive and recurrent properties of ATC, its therapeutic options are mainly palliative. Therefore, there is an urgent need to find new therapeutic approaches, and targeted therapy in the ATC microenvironment may be a new way94. Polymorphonuclear neutrophils (PMNs) are critical effector cells that orchestrate the inflammatory response in TME. PMNs contain and release an excess of mediators, including granular enzymes [e.g., myeloperoxidase (MPO), pentraxin-3 (PTX3) and matrix metalloproteinase-9 (MMP-9)], and neutrophil extracellular traps (NETs), and those seem to correlate with malignancy and severity of progressive thyroid tumor95. Cristinziano et al.96 discovered that conditioned media with ATC cell lines induced the release of NETs, and thus targeting neutrophil activation may contribute to inhibiting ATC proliferation. In addition, the combination of BRAF inhibitors and immunotherapy in ATC is a promising therapeutic approach to maximize treatment efficacy. For example, combination therapy with the BRAFV600E inhibitor PLX4720 and an anti-PD-L1 or anti-PD-1 antibody significantly improved mouse survival, and the reduction in tumor volume was associated with an increase in the number and activity of effector immune cells97. Moreover, the interaction of ECM with cancer cells not only facilitates tumor development and progression, but also largely controls most of the characteristic hallmarks of tumorigenesis, providing new opportunities for the treatment of ATC.

Cancer progression is driven by continuous interactions between cancer cells, the ECM, and other cell types present in the TME. ECM components contribute significantly to the microenvironment of most individual cells in the body, and their dysregulation is closely linked to the development of many diseases, including cancer. However, the therapeutic role of EMT in thyroid cancer is often underestimated. The main challenge lies in the current lack of materials that accurately mimic the ECM in vitro due to its complex physical and biological properties, and the delicate interactions between different components of the ECM. There is a lack of systematic comparisons of differences in specific ECM components in different cancers, which is an essential step for the development of specific therapeutic and sensitive detection strategies. Therefore, current applications of the ECM in cancer primarily include adjuvant therapy for immunotherapy or are considered an imaging tool for tumors, and its central role in tumor therapy remains unexplored.

ATC is a subtype of thyroid cancer that occurs in a small percentage of patients but has a high degree of malignancy and poor patient prognosis. Clinically, it generally manifests as a fast-growing goiter or nodule that is firm to the touch and adheres resolutely to the underlying structures. We revealed the important role of ECM components in the malignant transformation of ATC, which suggested that ECM components were promising therapeutic targets. We hypothesized that cancer cells wrapped and hijacked the ECM to become part of the tumor microenvironment, which promoted the sending of signals of their own aggression to surrounding or distant tissues or organs and altered the state of the surrounding environment to form an immunosuppressive microenvironment that was conducive to the growth of cancer cells. Therefore, ATC undergoes significant infiltration and metastasis at an early stage.

During the malignant transformation of ATC, a variety of immune cells that were previously capable of tumor killing are transformed into promoters that advance the malignant progression of the tumor, including but not limited to the transformation of CD8+ T cells to depleted T cells and the polarization of macrophages to M2-type macrophages. These results suggest that cancer cells must release some signal or pressure to promote a decrease in immune cell activity in the TME. We hypothesize that the continuous interactions between the ECM and cancer cells play a crucial role in this process. Therefore, sufficient attention should be given to ECM-cancer cell interactions in future studies to reveal their key mechanisms in the process of cancer immunosuppression, which will provide new opportunities for the treatment of ATC (Fig. 5).Fig. 5 Schematic representation of the mechanisms underlying the potential role of the extracellular matrix in the tumor microenvironment (generated by FigDraw).

Author contributions

X.J.K. conceived and designed the study, performed the data analysis and interpretation. X.J.K., S.Y.Y., and C.X.X. wrote the manuscript. All authors reviewed the manuscript.

Funding

This work was supported by the Guizhou Provincial People’s Hospital Talent Fund (grant number 2023-41).

Data Availability

The original data contributing to the findings presented in the study were obtained from Assistant for Clinical Bioinformatics (https://www.aclbi.com/static/index.html#/). Further inquiries may be addressed to the corresponding author.

Competing interests

The authors declare no competing interests.

Consent for publication

The manuscript has never been submitted to more than one journal for simultaneous consideration. The submitted work is original and has not been published elsewhere in any form or language.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Tao Y New insights into immune cells and immunotherapy for thyroid cancer Immunol. Invest. 2023 52 8 1039 1064 10.1080/08820139.2023.2268656 37846977
Tao, Y. et al. New insights into immune cells and immunotherapy for thyroid cancer. Immunol. Invest. 52(8), 1039–1064 (2023).37846977 10.1080/08820139.2023.2268656
2. Wang J Customizing cancer treatment at the nanoscale: A focus on anaplastic thyroid cancer therapy J. Nanobiotechnol. 2023 21 1 374 10.1186/s12951-023-02094-9
Wang, J. et al. Customizing cancer treatment at the nanoscale: A focus on anaplastic thyroid cancer therapy. J. Nanobiotechnol. 21(1), 374 (2023).10.1186/s12951-023-02094-9
3. Bhattacharya S Advances and challenges in thyroid cancer: The interplay of genetic modulators, targeted therapies, and AI-driven approaches Life Sci. 2023 332 122110 10.1016/j.lfs.2023.122110 37734434
Bhattacharya, S. et al. Advances and challenges in thyroid cancer: The interplay of genetic modulators, targeted therapies, and AI-driven approaches. Life Sci. 332, 122110 (2023).37734434 10.1016/j.lfs.2023.122110
4. Abe I Lam AK Anaplastic thyroid carcinoma: Updates on WHO classification, clinicopathological features and staging Histol. Histopathol. 2021 36 3 239 248 33170501
Abe, I. & Lam, A. K. Anaplastic thyroid carcinoma: Updates on WHO classification, clinicopathological features and staging. Histol. Histopathol. 36(3), 239–248 (2021).33170501
5. Leandro-Garcia LJ Landa I Mechanistic insights of thyroid cancer progression Endocrinology 2023 164 9 bqad118 10.1210/endocr/bqad118 37503738
Leandro-Garcia, L. J. & Landa, I. Mechanistic insights of thyroid cancer progression. Endocrinology 164(9), bqad118 (2023).37503738 10.1210/endocr/bqad118
6. Luo H The nexus of dynamic T cell states and immune checkpoint blockade therapy in the periphery and tumor microenvironment Front. Immunol. 2023 14 1267918 10.3389/fimmu.2023.1267918 37881432
Luo, H. et al. The nexus of dynamic T cell states and immune checkpoint blockade therapy in the periphery and tumor microenvironment. Front. Immunol. 14, 1267918 (2023).37881432 10.3389/fimmu.2023.1267918
7. Asadi M. et al. Immune features of tumor microenvironment: A genetic spotlight. Cell Biochem. Biophys. 82(1), 107–118. 10.1007/s12013-023-01192-7 (2023).
8. Xiao Y Yu D Tumor microenvironment as a therapeutic target in cancer Pharmacol. Ther. 2021 221 107753 10.1016/j.pharmthera.2020.107753 33259885
Xiao, Y. & Yu, D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol. Ther. 221, 107753 (2021).33259885 10.1016/j.pharmthera.2020.107753
9. Hinshaw DC Shevde LA The tumor microenvironment innately modulates cancer progression Cancer Res. 2019 79 18 4557 4566 10.1158/0008-5472.CAN-18-3962 31350295
Hinshaw, D. C. & Shevde, L. A. The tumor microenvironment innately modulates cancer progression. Cancer Res. 79(18), 4557–4566 (2019).31350295 10.1158/0008-5472.CAN-18-3962
10. Lu X Immunotherapy for anaplastic thyroid carcinoma: The present and future Zhejiang da Xue Xue Bao Yi Xue Ban 2021 50 6 675 684 35347912
Lu, X. et al. Immunotherapy for anaplastic thyroid carcinoma: The present and future. Zhejiang da Xue Xue Bao Yi Xue Ban 50(6), 675–684 (2021).35347912
11. Pitt JM Targeting the tumor microenvironment: Removing obstruction to anticancer immune responses and immunotherapy Ann. Oncol. 2016 27 8 1482 1492 10.1093/annonc/mdw168 27069014
Pitt, J. M. et al. Targeting the tumor microenvironment: Removing obstruction to anticancer immune responses and immunotherapy. Ann. Oncol. 27(8), 1482–1492 (2016).27069014 10.1093/annonc/mdw168
12. Mao X Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: New findings and future perspectives Mol. Cancer 2021 20 1 131 10.1186/s12943-021-01428-1 34635121
Mao, X. et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: New findings and future perspectives. Mol. Cancer 20(1), 131 (2021).34635121 10.1186/s12943-021-01428-1
13. Najafi M Farhood B Mortezaee K Extracellular matrix (ECM) stiffness and degradation as cancer drivers J. Cell Biochem. 2019 120 3 2782 2790 10.1002/jcb.27681 30321449
Najafi, M., Farhood, B. & Mortezaee, K. Extracellular matrix (ECM) stiffness and degradation as cancer drivers. J. Cell Biochem. 120(3), 2782–2790 (2019).30321449 10.1002/jcb.27681
14. Mohan V Das A Sagi I Emerging roles of ECM remodeling processes in cancer Semin. Cancer Biol. 2020 62 192 200 10.1016/j.semcancer.2019.09.004 31518697
Mohan, V., Das, A. & Sagi, I. Emerging roles of ECM remodeling processes in cancer. Semin. Cancer Biol. 62, 192–200 (2020).31518697 10.1016/j.semcancer.2019.09.004
15. Belli C Targeting the microenvironment in solid tumors Cancer Treat. Rev. 2018 65 22 32 10.1016/j.ctrv.2018.02.004 29502037
Belli, C. et al. Targeting the microenvironment in solid tumors. Cancer Treat. Rev. 65, 22–32 (2018).29502037 10.1016/j.ctrv.2018.02.004
16. Yang H Tumor-infiltrating lymphocytes are functionally inactivated by CD90+ stromal cells and reactivated by combined Ibrutinib and Rapamycin in human pleural mesothelioma Theranostics 2022 12 1 167 185 10.7150/thno.61209 34987640
Yang, H. et al. Tumor-infiltrating lymphocytes are functionally inactivated by CD90+ stromal cells and reactivated by combined Ibrutinib and Rapamycin in human pleural mesothelioma. Theranostics 12(1), 167–185 (2022).34987640 10.7150/thno.61209
17. Zhao G Tunicamycin promotes metastasis through upregulating endoplasmic reticulum stress induced GRP78 expression in thyroid carcinoma Cell Biosci. 2020 10 115 10.1186/s13578-020-00478-0 33014334
Zhao, G. et al. Tunicamycin promotes metastasis through upregulating endoplasmic reticulum stress induced GRP78 expression in thyroid carcinoma. Cell Biosci. 10, 115 (2020).33014334 10.1186/s13578-020-00478-0
18. Xia JK Deregulated bile acids may drive hepatocellular carcinoma metastasis by inducing an immunosuppressive microenvironment Front. Oncol. 2022 12 1033145 10.3389/fonc.2022.1033145 36338764
Xia, J. K. et al. Deregulated bile acids may drive hepatocellular carcinoma metastasis by inducing an immunosuppressive microenvironment. Front. Oncol. 12, 1033145 (2022).36338764 10.3389/fonc.2022.1033145
19. Ning J METTL3 inhibition induced by M2 macrophage-derived extracellular vesicles drives anti-PD-1 therapy resistance via M6A-CD70-mediated immune suppression in thyroid cancer Cell Death Differ. 2023 30 10 2265 2279 10.1038/s41418-023-01217-x 37648786
Ning, J. et al. METTL3 inhibition induced by M2 macrophage-derived extracellular vesicles drives anti-PD-1 therapy resistance via M6A-CD70-mediated immune suppression in thyroid cancer. Cell Death Differ. 30(10), 2265–2279 (2023).37648786 10.1038/s41418-023-01217-x
20. Bao L Targeting SIGLEC15 as an emerging immunotherapy for anaplastic thyroid cancer Int. Immunopharmacol. 2024 133 112102 10.1016/j.intimp.2024.112102 38652971
Bao, L. et al. Targeting SIGLEC15 as an emerging immunotherapy for anaplastic thyroid cancer. Int. Immunopharmacol. 133, 112102 (2024).38652971 10.1016/j.intimp.2024.112102
21. Weber F Increased cytoplasmatic expression of cancer immune surveillance receptor CD1d in anaplastic thyroid carcinomas Cancer Med. 2019 8 16 7065 7073 10.1002/cam4.2573 31560833
Weber, F. et al. Increased cytoplasmatic expression of cancer immune surveillance receptor CD1d in anaplastic thyroid carcinomas. Cancer Med. 8(16), 7065–7073 (2019).31560833 10.1002/cam4.2573
22. Huang Y Identification of an immune-related key gene, PPARGC1A, in the development of anaplastic thyroid carcinoma: In-silico study and in-vitro evaluation Minerva Endocrinol. (Torino) 2022 47 2 150 159 32720497
Huang, Y. et al. Identification of an immune-related key gene, PPARGC1A, in the development of anaplastic thyroid carcinoma: In-silico study and in-vitro evaluation. Minerva Endocrinol. (Torino) 47(2), 150–159 (2022).32720497
23. Xu T Immunological characteristics of immunogenic cell death genes and malignant progression driving roles of TLR4 in anaplastic thyroid carcinoma BMC Cancer 2023 23 1 1131 10.1186/s12885-023-11647-y 37990304
Xu, T. et al. Immunological characteristics of immunogenic cell death genes and malignant progression driving roles of TLR4 in anaplastic thyroid carcinoma. BMC Cancer 23(1), 1131 (2023).37990304 10.1186/s12885-023-11647-y
24. Das S Tumor cell-derived IL1beta promotes desmoplasia and immune suppression in pancreatic cancer Cancer Res. 2020 80 5 1088 1101 10.1158/0008-5472.CAN-19-2080 31915130
Das, S. et al. Tumor cell-derived IL1beta promotes desmoplasia and immune suppression in pancreatic cancer. Cancer Res. 80(5), 1088–1101 (2020).31915130 10.1158/0008-5472.CAN-19-2080
25. Gupta R Epigenetic regulation and targeting of ECM for cancer therapy Am. J. Physiol. Cell Physiol. 2022 322 4 C762 C768 10.1152/ajpcell.00022.2022 35235427
Gupta, R. Epigenetic regulation and targeting of ECM for cancer therapy. Am. J. Physiol. Cell Physiol. 322(4), C762–C768 (2022).35235427 10.1152/ajpcell.00022.2022
26. Yuzhalin AE Dynamic matrisome: ECM remodeling factors licensing cancer progression and metastasis Biochim. Biophys. Acta Rev. Cancer 2018 1870 2 207 228 10.1016/j.bbcan.2018.09.002 30316942
Yuzhalin, A. E. et al. Dynamic matrisome: ECM remodeling factors licensing cancer progression and metastasis. Biochim. Biophys. Acta Rev. Cancer 1870(2), 207–228 (2018).30316942 10.1016/j.bbcan.2018.09.002
27. De Martino D Bravo-Cordero JJ Collagens in cancer: Structural regulators and guardians of cancer progression Cancer Res. 2023 83 9 1386 1392 10.1158/0008-5472.CAN-22-2034 36638361
De Martino, D. & Bravo-Cordero, J. J. Collagens in cancer: Structural regulators and guardians of cancer progression. Cancer Res. 83(9), 1386–1392 (2023).36638361 10.1158/0008-5472.CAN-22-2034
28. Chen Y Oncogenic collagen I homotrimers from cancer cells bind to alpha3beta1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer Cancer Cell 2022 40 8 818 834.E9 10.1016/j.ccell.2022.06.011 35868307
Chen, Y. et al. Oncogenic collagen I homotrimers from cancer cells bind to alpha3beta1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer. Cancer Cell 40(8), 818-834.E9 (2022).35868307 10.1016/j.ccell.2022.06.011
29. Niu J Identification of the collagen family as prognostic biomarkers in papillary thyroid carcinoma Endocrine 2022 78 3 491 506 10.1007/s12020-022-03175-9 36070051
Niu, J. et al. Identification of the collagen family as prognostic biomarkers in papillary thyroid carcinoma. Endocrine 78(3), 491–506 (2022).36070051 10.1007/s12020-022-03175-9
30. Di Martino JS A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy Nat. Cancer 2022 3 1 90 107 10.1038/s43018-021-00291-9 35121989
Di Martino, J. S. et al. A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy. Nat. Cancer 3(1), 90–107 (2022).35121989 10.1038/s43018-021-00291-9
31. Chen Y Type I collagen deletion in alphaSMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer Cancer Cell 2021 39 4 548 565.E6 10.1016/j.ccell.2021.02.007 33667385
Chen, Y. et al. Type I collagen deletion in alphaSMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer. Cancer Cell 39(4), 548-565.E6 (2021).33667385 10.1016/j.ccell.2021.02.007
32. Xu S The role of collagen in cancer: From bench to bedside J. Transl. Med. 2019 17 1 309 10.1186/s12967-019-2058-1 31521169
Xu, S. et al. The role of collagen in cancer: From bench to bedside. J. Transl. Med. 17(1), 309 (2019).31521169 10.1186/s12967-019-2058-1
33. Romer AMA Thorseth ML Madsen DH Immune modulatory properties of collagen in cancer Front. Immunol. 2021 12 791453 10.3389/fimmu.2021.791453 34956223
Romer, A. M. A., Thorseth, M. L. & Madsen, D. H. Immune modulatory properties of collagen in cancer. Front. Immunol. 12, 791453 (2021).34956223 10.3389/fimmu.2021.791453
34. Jablonska-Trypuc A Matejczyk M Rosochacki S Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs J. Enzym. Inhib. Med. Chem. 2016 31 sup1 177 183 10.3109/14756366.2016.1161620
Jablonska-Trypuc, A., Matejczyk, M. & Rosochacki, S. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. J. Enzym. Inhib. Med. Chem. 31(sup1), 177–183 (2016).10.3109/14756366.2016.1161620
35. Huang C The prognostic potential of alpha-1 type I collagen expression in papillary thyroid cancer Biochem. Biophys. Res. Commun. 2019 515 1 125 132 10.1016/j.bbrc.2019.04.119 31128912
Huang, C. et al. The prognostic potential of alpha-1 type I collagen expression in papillary thyroid cancer. Biochem. Biophys. Res. Commun. 515(1), 125–132 (2019).31128912 10.1016/j.bbrc.2019.04.119
36. Ivkovic I Role of matrix metalloproteinases and their inhibitors in locally invasive papillary thyroid cancer Biomedicines 2022 10 12 3178 10.3390/biomedicines10123178 36551933
Ivkovic, I. et al. Role of matrix metalloproteinases and their inhibitors in locally invasive papillary thyroid cancer. Biomedicines 10(12), 3178 (2022).36551933 10.3390/biomedicines10123178
37. Kameyama K Expression of MMP-1 in the capsule of thyroid cancer–relationship with invasiveness Pathol. Res. Pract. 1996 192 1 20 26 10.1016/S0344-0338(96)80125-7 8685037
Kameyama, K. Expression of MMP-1 in the capsule of thyroid cancer–relationship with invasiveness. Pathol. Res. Pract. 192(1), 20–26 (1996).8685037 10.1016/S0344-0338(96)80125-7
38. Lu L Anaplastic transformation in thyroid cancer revealed by single-cell transcriptomics J. Clin. Invest. 2023 133 11 e169653 10.1172/JCI169653 37053016
Lu, L. et al. Anaplastic transformation in thyroid cancer revealed by single-cell transcriptomics. J. Clin. Invest. 133(11), e169653 (2023).37053016 10.1172/JCI169653
39. Chen Y CTHRC1 promotes anaplastic thyroid cancer progression by upregulating the proliferation, migration, and invasion of tumor cells PeerJ 2023 11 e15458 10.7717/peerj.15458 37273536
Chen, Y. et al. CTHRC1 promotes anaplastic thyroid cancer progression by upregulating the proliferation, migration, and invasion of tumor cells. PeerJ 11, e15458 (2023).37273536 10.7717/peerj.15458
40. Yoshida T Membrane type 1 matrix metalloproteinase regulates anaplastic thyroid carcinoma cell growth and invasion into the collagen matrix Biochem. Biophys. Res. Commun. 2020 529 4 1195 1200 10.1016/j.bbrc.2020.06.043 32819585
Yoshida, T. et al. Membrane type 1 matrix metalloproteinase regulates anaplastic thyroid carcinoma cell growth and invasion into the collagen matrix. Biochem. Biophys. Res. Commun. 529(4), 1195–1200 (2020).32819585 10.1016/j.bbrc.2020.06.043
41. Pan Z CREB3L1 promotes tumor growth and metastasis of anaplastic thyroid carcinoma by remodeling the tumor microenvironment Mol. Cancer 2022 21 1 190 10.1186/s12943-022-01658-x 36192735
Pan, Z. et al. CREB3L1 promotes tumor growth and metastasis of anaplastic thyroid carcinoma by remodeling the tumor microenvironment. Mol. Cancer 21(1), 190 (2022).36192735 10.1186/s12943-022-01658-x
42. Angre T Role of collagen regulators in cancer treatment: A comprehensive review Anticancer Agents Med. Chem. 2022 22 17 2956 2984 10.2174/1871520622666220501162351 35490431
Angre, T. et al. Role of collagen regulators in cancer treatment: A comprehensive review. Anticancer Agents Med. Chem. 22(17), 2956–2984 (2022).35490431 10.2174/1871520622666220501162351
43. Lin TC Fibronectin in cancer: Friend or foe Cells 2019 9 1 27 10.3390/cells9010027 31861892
Lin, T. C. et al. Fibronectin in cancer: Friend or foe. Cells 9(1), 27 (2019).31861892 10.3390/cells9010027
44. Rick JW Fibronectin in malignancy: Cancer-specific alterations, protumoral effects, and therapeutic implications Semin. Oncol. 2019 46 3 284 290 10.1053/j.seminoncol.2019.08.002 31488338
Rick, J. W. et al. Fibronectin in malignancy: Cancer-specific alterations, protumoral effects, and therapeutic implications. Semin. Oncol. 46(3), 284–290 (2019).31488338 10.1053/j.seminoncol.2019.08.002
45. Kumra H Reinhardt DP Fibronectin-targeted drug delivery in cancer Adv. Drug Deliv. Rev. 2016 97 101 110 10.1016/j.addr.2015.11.014 26639577
Kumra, H. & Reinhardt, D. P. Fibronectin-targeted drug delivery in cancer. Adv. Drug Deliv. Rev. 97, 101–110 (2016).26639577 10.1016/j.addr.2015.11.014
46. Farooq F Shielding and nurturing: Fibronectin as a modulator of cancer drug resistance J. Cell Physiol. 2023 238 8 1651 1669 10.1002/jcp.31048 37269547
Farooq, F. et al. Shielding and nurturing: Fibronectin as a modulator of cancer drug resistance. J. Cell Physiol. 238(8), 1651–1669 (2023).37269547 10.1002/jcp.31048
47. Cox TR The matrix in cancer Nat. Rev. Cancer 2021 21 4 217 238 10.1038/s41568-020-00329-7 33589810
Cox, T. R. The matrix in cancer. Nat. Rev. Cancer 21(4), 217–238 (2021).33589810 10.1038/s41568-020-00329-7
48. Li J Elastin is a key factor of tumor development in colorectal cancer BMC Cancer 2020 20 1 217 10.1186/s12885-020-6686-x 32171282
Li, J. et al. Elastin is a key factor of tumor development in colorectal cancer. BMC Cancer 20(1), 217 (2020).32171282 10.1186/s12885-020-6686-x
49. Ruan J Exogenous laminin exhibits a unique vascular pattern in the brain via binding to dystroglycan and integrins Fluids Barriers CNS 2022 19 1 97 10.1186/s12987-022-00396-y 36463265
Ruan, J. et al. Exogenous laminin exhibits a unique vascular pattern in the brain via binding to dystroglycan and integrins. Fluids Barriers CNS 19(1), 97 (2022).36463265 10.1186/s12987-022-00396-y
50. Mori T Downregulation of a newly identified laminin, laminin-3B11, in vascular basement membranes of invasive human breast cancers Cancer Sci. 2011 102 5 1095 1100 10.1111/j.1349-7006.2011.01892.x 21276136
Mori, T. et al. Downregulation of a newly identified laminin, laminin-3B11, in vascular basement membranes of invasive human breast cancers. Cancer Sci. 102(5), 1095–1100 (2011).21276136 10.1111/j.1349-7006.2011.01892.x
51. Vasvani S Kulkarni P Rawtani D Hyaluronic acid: A review on its biology, aspects of drug delivery, route of administrations and a special emphasis on its approved marketed products and recent clinical studies Int. J. Biol. Macromol. 2020 151 1012 1029 10.1016/j.ijbiomac.2019.11.066 31715233
Vasvani, S., Kulkarni, P. & Rawtani, D. Hyaluronic acid: A review on its biology, aspects of drug delivery, route of administrations and a special emphasis on its approved marketed products and recent clinical studies. Int. J. Biol. Macromol. 151, 1012–1029 (2020).31715233 10.1016/j.ijbiomac.2019.11.066
52. Abatangelo G Hyaluronic acid: Redefining its role Cells 2020 9 7 1743 10.3390/cells9071743 32708202
Abatangelo, G. et al. Hyaluronic acid: Redefining its role. Cells 9(7), 1743 (2020).32708202 10.3390/cells9071743
53. Della Sala F Advances in hyaluronic-acid-based (Nano) devices for cancer therapy Macromol. Biosci. 2022 22 1 e2100304 10.1002/mabi.202100304 34657388
Della Sala, F. et al. Advances in hyaluronic-acid-based (Nano) devices for cancer therapy. Macromol. Biosci. 22(1), e2100304 (2022).34657388 10.1002/mabi.202100304
54. Oh JM Different expression of thyroid-specific proteins in thyroid cancer cells between 2-dimensional (2D) and 3-dimensional (3D) culture environment Cells 2022 11 22 3559 10.3390/cells11223559 36428988
Oh, J. M. et al. Different expression of thyroid-specific proteins in thyroid cancer cells between 2-dimensional (2D) and 3-dimensional (3D) culture environment. Cells 11(22), 3559 (2022).36428988 10.3390/cells11223559
55. Moretti L The interplay of fibroblasts, the extracellular matrix, and inflammation in scar formation J. Biol. Chem. 2022 298 2 101530 10.1016/j.jbc.2021.101530 34953859
Moretti, L. et al. The interplay of fibroblasts, the extracellular matrix, and inflammation in scar formation. J. Biol. Chem. 298(2), 101530 (2022).34953859 10.1016/j.jbc.2021.101530
56. Haydont V Fibroblasts from the human skin dermo-hypodermal junction are distinct from dermal papillary and reticular fibroblasts and from mesenchymal stem cells and exhibit a specific molecular profile related to extracellular matrix organization and modeling Cells 2020 9 2 368 10.3390/cells9020368 32033496
Haydont, V. et al. Fibroblasts from the human skin dermo-hypodermal junction are distinct from dermal papillary and reticular fibroblasts and from mesenchymal stem cells and exhibit a specific molecular profile related to extracellular matrix organization and modeling. Cells 9(2), 368 (2020).32033496 10.3390/cells9020368
57. Peng D Targeting TGF-beta signal transduction for fibrosis and cancer therapy Mol. Cancer 2022 21 1 104 10.1186/s12943-022-01569-x 35461253
Peng, D. et al. Targeting TGF-beta signal transduction for fibrosis and cancer therapy. Mol. Cancer 21(1), 104 (2022).35461253 10.1186/s12943-022-01569-x
58. Chakravarthy A TGF-beta-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure Nat. Commun. 2018 9 1 4692 10.1038/s41467-018-06654-8 30410077
Chakravarthy, A. et al. TGF-beta-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. Nat. Commun. 9(1), 4692 (2018).30410077 10.1038/s41467-018-06654-8
59. Fozzatti L Cheng SY Tumor cells and cancer-associated fibroblasts: A synergistic crosstalk to promote thyroid cancer Endocrinol. Metab. (Seoul) 2020 35 4 673 680 10.3803/EnM.2020.401 33161690
Fozzatti, L. & Cheng, S. Y. Tumor cells and cancer-associated fibroblasts: A synergistic crosstalk to promote thyroid cancer. Endocrinol. Metab. (Seoul) 35(4), 673–680 (2020).33161690 10.3803/EnM.2020.401
60. Jolly LA Fibroblast-mediated collagen remodeling within the tumor microenvironment facilitates progression of thyroid cancers driven by BrafV600E and Pten loss Cancer Res. 2016 76 7 1804 1813 10.1158/0008-5472.CAN-15-2351 26818109
Jolly, L. A. et al. Fibroblast-mediated collagen remodeling within the tumor microenvironment facilitates progression of thyroid cancers driven by BrafV600E and Pten loss. Cancer Res. 76(7), 1804–1813 (2016).26818109 10.1158/0008-5472.CAN-15-2351
61. Zhu L Cancer-associated fibroblasts in papillary thyroid carcinoma Clin. Exp. Med. 2023 23 6 2209 2220 10.1007/s10238-023-00998-2 36715834
Zhu, L. et al. Cancer-associated fibroblasts in papillary thyroid carcinoma. Clin. Exp. Med. 23(6), 2209–2220 (2023).36715834 10.1007/s10238-023-00998-2
62. Hu H Transcriptome analysis revealed potential neuro-immune interaction in papillary thyroid carcinoma tissues Diseases 2023 11 1 9 10.3390/diseases11010009 36648874
Hu, H. et al. Transcriptome analysis revealed potential neuro-immune interaction in papillary thyroid carcinoma tissues. Diseases 11(1), 9 (2023).36648874 10.3390/diseases11010009
63. Minna E Cancer associated fibroblasts and senescent thyroid cells in the invasive front of thyroid carcinoma Cancers (Basel) 2020 12 1 112 10.3390/cancers12010112 31906302
Minna, E. et al. Cancer associated fibroblasts and senescent thyroid cells in the invasive front of thyroid carcinoma. Cancers (Basel) 12(1), 112 (2020).31906302 10.3390/cancers12010112
64. Chakraborty S Disruption of cell-cell communication in anaplastic thyroid cancer as an immunotherapeutic opportunity Adv. Exp. Med. Biol. 2021 1350 33 66 10.1007/978-3-030-83282-7_2 34888843
Chakraborty, S. et al. Disruption of cell-cell communication in anaplastic thyroid cancer as an immunotherapeutic opportunity. Adv. Exp. Med. Biol. 1350, 33–66 (2021).34888843 10.1007/978-3-030-83282-7_2
65. Patwardhan S ECM stiffness-tuned exosomes drive breast cancer motility through thrombospondin-1 Biomaterials 2021 279 121185 10.1016/j.biomaterials.2021.121185 34808560
Patwardhan, S. et al. ECM stiffness-tuned exosomes drive breast cancer motility through thrombospondin-1. Biomaterials 279, 121185 (2021).34808560 10.1016/j.biomaterials.2021.121185
66. Jiang Y Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy J. Hematol. Oncol. 2022 15 1 34 10.1186/s13045-022-01252-0 35331296
Jiang, Y. et al. Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy. J. Hematol. Oncol. 15(1), 34 (2022).35331296 10.1186/s13045-022-01252-0
67. Huang J Extracellular matrix and its therapeutic potential for cancer treatment Signal Transduct. Target. Ther. 2021 6 1 153 10.1038/s41392-021-00544-0 33888679
Huang, J. et al. Extracellular matrix and its therapeutic potential for cancer treatment. Signal Transduct. Target. Ther. 6(1), 153 (2021).33888679 10.1038/s41392-021-00544-0
68. Pittayapruek P Role of matrix metalloproteinases in photoaging and photocarcinogenesis Int. J. Mol. Sci. 2016 17 6 868 10.3390/ijms17060868 27271600
Pittayapruek, P. et al. Role of matrix metalloproteinases in photoaging and photocarcinogenesis. Int. J. Mol. Sci. 17(6), 868 (2016).27271600 10.3390/ijms17060868
69. Thenappan T Chan SY Weir EK Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension Am. J. Physiol. Heart Circ. Physiol. 2018 315 5 H1322 H1331 10.1152/ajpheart.00136.2018 30141981
Thenappan, T., Chan, S. Y. & Weir, E. K. Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension. Am. J. Physiol. Heart Circ. Physiol. 315(5), H1322–H1331 (2018).30141981 10.1152/ajpheart.00136.2018
70. Mhaidly R Mechta-Grigoriou F Fibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies Semin. Immunol. 2020 48 101417 10.1016/j.smim.2020.101417 33077325
Mhaidly, R. & Mechta-Grigoriou, F. Fibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies. Semin. Immunol. 48, 101417 (2020).33077325 10.1016/j.smim.2020.101417
71. Freeman P Mielgo A Cancer-associated fibroblast mediated inhibition of CD8+ cytotoxic T cell accumulation in tumours: Mechanisms and therapeutic opportunities Cancers (Basel) 2020 12 9 2687 10.3390/cancers12092687 32967079
Freeman, P. & Mielgo, A. Cancer-associated fibroblast mediated inhibition of CD8+ cytotoxic T cell accumulation in tumours: Mechanisms and therapeutic opportunities. Cancers (Basel) 12(9), 2687 (2020).32967079 10.3390/cancers12092687
72. Horn LA Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-beta signaling enables PD-L1-mediated tumor eradication J. Clin. Invest. 2022 132 8 e155148 10.1172/JCI155148 35230974
Horn, L. A. et al. Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-beta signaling enables PD-L1-mediated tumor eradication. J. Clin. Invest. 132(8), e155148 (2022).35230974 10.1172/JCI155148
73. Alldinger S Roles of an extracellular matrix (ECM) receptor and ECM processing enzymes in demyelinating canine distemper encephalitis Dtsch. Tierarztl. Wochenschr. 2006 113 4 151-2 151-6 16716051
Alldinger, S. et al. Roles of an extracellular matrix (ECM) receptor and ECM processing enzymes in demyelinating canine distemper encephalitis. Dtsch. Tierarztl. Wochenschr. 113(4), 151-2–151-6 (2006).16716051
74. Niland S Riscanevo AX Eble JA Matrix metalloproteinases shape the tumor microenvironment in cancer progression Int. J. Mol. Sci. 2021 23 1 146 10.3390/ijms23010146 35008569
Niland, S., Riscanevo, A. X. & Eble, J. A. Matrix metalloproteinases shape the tumor microenvironment in cancer progression. Int. J. Mol. Sci. 23(1), 146 (2021).35008569 10.3390/ijms23010146
75. Yuan Z Extracellular matrix remodeling in tumor progression and immune escape: From mechanisms to treatments Mol. Cancer 2023 22 1 48 10.1186/s12943-023-01744-8 36906534
Yuan, Z. et al. Extracellular matrix remodeling in tumor progression and immune escape: From mechanisms to treatments. Mol. Cancer 22(1), 48 (2023).36906534 10.1186/s12943-023-01744-8
76. Mosquera MJ Extracellular matrix in synthetic hydrogel-based prostate cancer organoids regulate therapeutic response to EZH2 and DRD2 inhibitors Adv. Mater. 2022 34 2 e2100096 10.1002/adma.202100096 34676924
Mosquera, M. J. et al. Extracellular matrix in synthetic hydrogel-based prostate cancer organoids regulate therapeutic response to EZH2 and DRD2 inhibitors. Adv. Mater. 34(2), e2100096 (2022).34676924 10.1002/adma.202100096
77. Zhang W Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix Br. J. Cancer 2019 121 10 837 845 10.1038/s41416-019-0578-3 31570753
Zhang, W. et al. Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix. Br. J. Cancer 121(10), 837–845 (2019).31570753 10.1038/s41416-019-0578-3
78. Nakajima Y Critical role of the CD44lowCD62Llow CD8+ T cell subset in restoring antitumor immunity in aged mice Proc. Natl. Acad. Sci. U. S. A. 2021 118 23 e2103730118 10.1073/pnas.2103730118 34088845
Nakajima, Y. et al. Critical role of the CD44lowCD62Llow CD8+ T cell subset in restoring antitumor immunity in aged mice. Proc. Natl. Acad. Sci. U. S. A. 118(23), e2103730118 (2021).34088845 10.1073/pnas.2103730118
79. Kong T CD44 promotes PD-L1 expression and its tumor-intrinsic function in breast and lung cancers Cancer Res. 2020 80 3 444 457 10.1158/0008-5472.CAN-19-1108 31722999
Kong, T. et al. CD44 promotes PD-L1 expression and its tumor-intrinsic function in breast and lung cancers. Cancer Res. 80(3), 444–457 (2020).31722999 10.1158/0008-5472.CAN-19-1108
80. Ishikawa T Phase I clinical trial of fibronectin CH296-stimulated T cell therapy in patients with advanced cancer PLoS One 2014 9 1 e83786 10.1371/journal.pone.0083786 24497917
Ishikawa, T. et al. Phase I clinical trial of fibronectin CH296-stimulated T cell therapy in patients with advanced cancer. PLoS One 9(1), e83786 (2014).24497917 10.1371/journal.pone.0083786
81. Su H Karin M Collagen architecture and signaling orchestrate cancer development Trends Cancer 2023 9 9 764 773 10.1016/j.trecan.2023.06.002 37400314
Su, H. & Karin, M. Collagen architecture and signaling orchestrate cancer development. Trends Cancer 9(9), 764–773 (2023).37400314 10.1016/j.trecan.2023.06.002
82. Martins Cavaco AC Collagen biology making inroads into prognosis and treatment of cancer progression and metastasis Cancer Metastasis Rev. 2020 39 3 603 623 10.1007/s10555-020-09888-5 32447477
Martins Cavaco, A. C. et al. Collagen biology making inroads into prognosis and treatment of cancer progression and metastasis. Cancer Metastasis Rev. 39(3), 603–623 (2020).32447477 10.1007/s10555-020-09888-5
83. Chen P Cescon M Bonaldo P Collagen VI in cancer and its biological mechanisms Trends Mol. Med. 2013 19 7 410 417 10.1016/j.molmed.2013.04.001 23639582
Chen, P., Cescon, M. & Bonaldo, P. Collagen VI in cancer and its biological mechanisms. Trends Mol. Med. 19(7), 410–417 (2013).23639582 10.1016/j.molmed.2013.04.001
84. Sarwar M Collagen I dysregulation is pivotal for ovarian cancer progression Tissue Cell 2022 74 101704 10.1016/j.tice.2021.101704 34871826
Sarwar, M. et al. Collagen I dysregulation is pivotal for ovarian cancer progression. Tissue Cell 74, 101704 (2022).34871826 10.1016/j.tice.2021.101704
85. Nissen NI Karsdal M Willumsen N Collagens and cancer associated fibroblasts in the reactive stroma and its relation to cancer biology J. Exp. Clin. Cancer Res. 2019 38 1 115 10.1186/s13046-019-1110-6 30841909
Nissen, N. I., Karsdal, M. & Willumsen, N. Collagens and cancer associated fibroblasts in the reactive stroma and its relation to cancer biology. J. Exp. Clin. Cancer Res. 38(1), 115 (2019).30841909 10.1186/s13046-019-1110-6
86. Zinger A Collagenase nanoparticles enhance the penetration of drugs into pancreatic tumors ACS Nano 2019 13 10 11008 11021 10.1021/acsnano.9b02395 31503443
Zinger, A. et al. Collagenase nanoparticles enhance the penetration of drugs into pancreatic tumors. ACS Nano 13(10), 11008–11021 (2019).31503443 10.1021/acsnano.9b02395
87. Boufraqech M miR30a inhibits LOX expression and anaplastic thyroid cancer progression Cancer Res. 2015 75 2 367 377 10.1158/0008-5472.CAN-14-2304 25488748
Boufraqech, M. et al. miR30a inhibits LOX expression and anaplastic thyroid cancer progression. Cancer Res. 75(2), 367–377 (2015).25488748 10.1158/0008-5472.CAN-14-2304
88. Muir AJ Simtuzumab for primary sclerosing cholangitis: Phase 2 study results with insights on the natural history of the disease Hepatology 2019 69 2 684 698 10.1002/hep.30237 30153359
Muir, A. J. et al. Simtuzumab for primary sclerosing cholangitis: Phase 2 study results with insights on the natural history of the disease. Hepatology 69(2), 684–698 (2019).30153359 10.1002/hep.30237
89. Raghu G Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: A randomised, double-blind, controlled, phase 2 trial Lancet Respir. Med. 2017 5 1 22 32 10.1016/S2213-2600(16)30421-0 27939076
Raghu, G. et al. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: A randomised, double-blind, controlled, phase 2 trial. Lancet Respir. Med. 5(1), 22–32 (2017).27939076 10.1016/S2213-2600(16)30421-0
90. Hatfield KJ Reikvam H Bruserud O The crosstalk between the matrix metalloprotease system and the chemokine network in acute myeloid leukemia Curr. Med. Chem. 2010 17 36 4448 4461 10.2174/092986710794183033 21062258
Hatfield, K. J., Reikvam, H. & Bruserud, O. The crosstalk between the matrix metalloprotease system and the chemokine network in acute myeloid leukemia. Curr. Med. Chem. 17(36), 4448–4461 (2010).21062258 10.2174/092986710794183033
91. de Rooij MF The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia Blood 2012 119 11 2590 2594 10.1182/blood-2011-11-390989 22279054
de Rooij, M. F. et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 119(11), 2590–2594 (2012).22279054 10.1182/blood-2011-11-390989
92. Pilarski LM Potential role for hyaluronan and the hyaluronan receptor RHAMM in mobilization and trafficking of hematopoietic progenitor cells Blood 1999 93 9 2918 2927 10.1182/blood.V93.9.2918.409k19_2918_2927 10216086
Pilarski, L. M. et al. Potential role for hyaluronan and the hyaluronan receptor RHAMM in mobilization and trafficking of hematopoietic progenitor cells. Blood 93(9), 2918–2927 (1999).10216086 10.1182/blood.V93.9.2918.409k19_2918_2927
93. Schmitt M RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses Blood 2008 111 3 1357 1365 10.1182/blood-2007-07-099366 17978170
Schmitt, M. et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood 111(3), 1357–1365 (2008).17978170 10.1182/blood-2007-07-099366
94. Ferrari SM Immune and inflammatory cells in thyroid cancer microenvironment Int. J. Mol. Sci. 2019 20 18 4413 10.3390/ijms20184413 31500315
Ferrari, S. M. et al. Immune and inflammatory cells in thyroid cancer microenvironment. Int. J. Mol. Sci. 20(18), 4413 (2019).31500315 10.3390/ijms20184413
95. Modestino L Neutrophil extracellular traps and neutrophil-related mediators in human thyroid cancer Front. Immunol. 2023 14 1167404 10.3389/fimmu.2023.1167404 37705974
Modestino, L. et al. Neutrophil extracellular traps and neutrophil-related mediators in human thyroid cancer. Front. Immunol. 14, 1167404 (2023).37705974 10.3389/fimmu.2023.1167404
96. Cristinziano L Anaplastic thyroid cancer cells Induce the release of mitochondrial extracellular DNA traps by viable neutrophils J. Immunol. 2020 204 5 1362 1372 10.4049/jimmunol.1900543 31959732
Cristinziano, L. et al. Anaplastic thyroid cancer cells Induce the release of mitochondrial extracellular DNA traps by viable neutrophils. J. Immunol. 204(5), 1362–1372 (2020).31959732 10.4049/jimmunol.1900543
97. Gunda V Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer Br. J. Cancer 2018 119 10 1223 1232 10.1038/s41416-018-0296-2 30327563
Gunda, V. et al. Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer. Br. J. Cancer 119(10), 1223–1232 (2018).30327563 10.1038/s41416-018-0296-2
